Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ascentage Pharma HQP1351 bioavailable inhibitor · 1 trial · 5 indications
To evaluate the Maximum Plasma Concentration (Cmax) of HQP1351
To evaluate the Area Under the Curve (AUC) of HQP1351
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | - |
| Cohort B | EXPERIMENTAL | - |
| Cohort C | EXPERIMENTAL | - |
| Cohort D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ascentage Pharma HQP1351 bioavailable inhibitor | DRUG | HQP1351 taken by mouth every other day |
| Blinatumomab | DRUG | Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7). |
Inclusion Criteria: * For HQP1351 monotherapy, patients must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL, with or without T315I mutation * For Cohort D, patients with Ph+ BCP ALL or CML LBP must be resistant or intolerant to at least one second or later generation TKI, such as...
Ascentage Pharma HQP1351 is an investigational small molecule being studied for the treatment of chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia. It is currently in Phase 1 clinical development for these blood cancers.
HQP1351 is a bioavailable inhibitor being developed by Ascentage Pharma. The specific molecular target is not disclosed in the available information, so its mechanism of action is not described here.
HQP1351 is being developed by Ascentage Pharma Group International, which trades under the ticker AAPG. The company is conducting clinical trials for this investigational drug in the United States and Canada.
HQP1351 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is actively recruiting participants.
HQP1351 is being studied in a Phase 1 clinical trial with the identifier NCT04260022. This trial is recruiting 242 participants with refractory chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia in the United States and Canada.
Yes, HQP1351 is the same drug as Ascentage Pharma HQP1351. The drug is referred to by its code name HQP1351 in clinical trial records and is being developed by Ascentage Pharma Group International.